About Jeito Capital
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito life or LinkedIn.
About Pulmocide
Pulmocide Ltd (www.pulmocide.com) is a late-stage biopharmaceutical company developing novel therapies for patients suffering from serious acute and chronic respiratory diseases. Pulmocide’s lead product is PC945, a novel antifungal specifically designed for inhaled use to maximize the amount of drug in the lung
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.